| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 23,170 | 19,600 | 11,800 | 303,300 |
| Cost of goods sold | 7,385 | 1,636 | 10,570 | 8,729 |
| Gross profit | 15,785 | 17,964 | 1,230 | 294,571 |
| Research and development | 1,926,311 | 3,559,712 | 2,594,750 | 2,225,882 |
| General and administrative | 1,475,207 | 283,552 | 1,115,491 | 1,373,976 |
| Total operating expenses | 3,401,518 | 3,843,264 | 3,710,241 | 3,599,858 |
| Loss from operations | -3,385,733 | -3,825,300 | -3,709,011 | -3,305,287 |
| Interest income, net | NaN | 34,586 | 57,740 | 73,915 |
| Dividend and interest income, net | 5,479 | NaN | NaN | NaN |
| Other income | 5,728 | 14,112 | 930 | 518 |
| Change in fair value of warrant liabilities | 1,220,121 | 568,966 | 612,064 | 574,591 |
| Gain on exchange of warrants | NaN | NaN | NaN | 0 |
| Total other income (expense) | 1,231,328 | 617,664 | 670,734 | 649,024 |
| Net loss | -2,154,405 | -3,207,636 | -3,038,277 | -2,656,263 |
| Basic EPS | -0.12 | -0.329 | -0.33 | -0.3 |
| Diluted EPS | -0.12 | -0.329 | -0.33 | -0.3 |
| Basic Average Shares | 17,727,747 | 9,758,763 | 9,116,172 | 8,740,382 |
| Diluted Average Shares | 17,727,747 | 9,758,763 | 9,116,172 | 8,740,382 |
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)